Theracodophen-Low-90 description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Theracodophen-Low-90

Physician Therapeutics LLC

Theracodophen-Low-90




FULL PRESCRIBING INFORMATION

NDC 53746-111-05

Hydrocodone
Bitartrate and
Acetominophen
Tablets, USP

Multiple Strengths:
Do not dispense unless
strength is stated.

Rx only      500 TABLETS

Each tablet contains:

hydrocodone bitartrate                5 mg
acetaminophen                          500 mg

Usual adult dosage: See package insert.

Store at 25 degrees C (77 degrees F); excursions permitted to 15 degrees - 30 degrees C
(59 - 86 degrees F). [See USP Controlled Room Temperature].

Dispense in tight, light-resistant container as defined in the USP.

Protect from light.

Do not accept if inner seal is broken or missing.

Manufactured by:    Amneal Pharmaceticals of NY
                             Hauppauge, NY 11788

Distributed by:        Amneal Pharmaceuticals
                             Glasgow, KY 42141

Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration.

Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as fine, white crystals or as a crystalline powder. It is affected by light.
The chemical name is 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula:

Theracodophen-Low-90

Acetaminophen, 4’-Hyroxyacetanilide, a slightly bitter, white, odorless,  crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:

Theracodophen-Low-90




Hydrocodone Bitartrate and Acetaminophen Tablets USP for oral administration
are available in a variety of strengths as described in the following table.

Strength                          Hydrocodone Bitartrate                    Acetaminophen
2.5 mg/500mg                           2.5mg                                       500mg
5mg/500mg                               5mg                                         500mg
7.5mg/325mg                            7.5mg                                       325mg
7.5mg/500mg                            7.5mg                                       500mg
7.5mg/650mg                            7.5mg                                       650mg
7.5mg/750mg                            7.5mg                                       750mg
10mg/325mg                             10mg                                        325mg
10mg/500mg                             10mg                                        500mg
10mg/650mg                             10mg                                        650mg
10mg/660mg                             10mg                                        660mg
10mg/750mg                             10mg                                        750mg

In addition, each tablet contains the following inactive ingredients:
anhydrous lactose, croscarmellose sodium, crospovidone, magnesium  stearate, microcrystalline cellulose, povidone, starch and stearic acid; except the 7.5 mg/325 mg, 10 mg/325 mg and 10 mg/500 mg tablets do not contain anhydrous lactose. The 7.5 mg/325 mg tablets include FD and C Yellow Number 6 Aluminum Lake; the 7.5 mg/650 mg tablets include FD and C Red Number 40 Aluminum Lake; the 10 mg/325 mg and 10 mg/750 mg tablets include D and C Yellow Number 10 Aluminum Lake; the 10 mg/500  mg include FD and C Blue Number 2 Aluminum Lake; and the 10 mg/650 mg  tablets include FD and C Blue Number 1 Aluminum Lake and D and C Yellow  number 10 Aluminum Lake. Meets USP Dissolution Test 1.
















Uses

Hydrocodone and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain.

















































The most frequently reported adverse reactions are lightheadedness, dizziness, sedation, nausea and vomiting. These effects seem to be more prominent in ambulatory than in  nonambulatory patients, and some of these adverse reactions may be alleviated if the
patient lies down.

Other adverse reactions include:
Central Nervous System: Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychic dependence, mood changes.

Gastrointestinal System: Prolonged administration of hydrocodone bitartrate and acetaminophen tablets may produce constipation.

Genitourinary System: Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported with opiates.

Respiratory Depression: Hydrocodone bitartrate may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see OVERDOSAGE).

Special Senses: Cases of hearing impairment or permanent loss have been reported predominantly in patients with chronic overdose.

Dermatological: Skin rash, pruritus.

The following adverse drug events may be borne in mind as potential effects of acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.

Potential effects of high dosage are listed in the OVERDOSAGE section.


Controlled Substance: Hydrocodone Bitartrate and Acetaminophen Tablets are classified as a Schedule III controlled substance.

Abuse and Dependence: Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of narcotics; therefore, this product should be prescribed and administered with caution. However, psychic dependence is unlikely
to develop when hydrocodone bitartrate and acetaminophen tablets are used for a short time for the treatment of pain.

Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients.




























2.5 mg/500 mg
5 mg/500 mg
The usual adult dosage is one or two tablets every four to six
hours as needed for pain. The total daily dose should not
exceed 8 tablets.
7.5 mg/325 mg
7.5 mg/500 mg
7.5 mg/650 mg
The usual adult dosage is one tablet every four to six hours
as needed for pain. The total daily dose should not exceed
6 tablets.
7.5 mg/750 mg The usual adult dosage is one tablet every four to six hours
as needed for pain. The total daily dose should not exceed
5 tablets.
10 mg/325 mg
10 mg/500 mg
10 mg/650 mg
10 mg/660 mg
The usual adult dosage is one tablet every four to six hours
as needed for pain. The total daily dose should not exceed
6 tablets.
10 mg/750 mg The usual adult dosage is one tablet every four to six hours
as needed for pain. The total daily dose should not exceed
5 tablets.











Hydrocodone Bitartrate and Acetominophen Tablets USP are available in the following strengths:

2.5 mg/500 mg      2.5 mg hydrocodone bitartrate and 500 mg acetaminophen,  oblong, white tablets bisected on one side and debossed  with WATSON 388 on the other side, supplied in bottles of  100.





on the other side, supplied in bottles of 100 and 500.

7.5 mg/650 mg      7.5 mg hydrocodone bitartrate and 650 mg acetaminophen,capsule-shaped, pink tablets bisected on one side  and debossed with WATSON 502 on the other side, supplied in bottles of 100 and 500.

7.5 mg/750 mg      7.5 mg hydrocodone bitartrate and 750 mg acetaminophen, capsule-shaped, white tablets bisected on one side and debossed with WATSON 387 on the other side, supplied in bottles of 100 and 500.

10 mg/325 mg       10 mg hydrocodone bitartrate and 325 mg acetaminophen,capsule-shaped, yellow tablets bisected on one side and debossed with WATSON 853 on the other side, supplied in bottles of 100 and 500.

10 mg/500 mg       10 mg hydrocodone bitartrate and 500 mg acetaminophen, capsule-shaped, blue tablets bisected on one side and debossed with WATSON 540 on the other side, supplied in bottles of 100 and 500.

10 mg/650 mg       10 mg hydrocodone bitartrate and 650 mg acetaminophen,capsule-shaped, light green tablets bisected on one side  and debossed with WATSON 503 on the other side, supplied in bottles of 100 and 500.

10 mg/660 mg       10 mg hydrocodone bitartrate and 660 mg acetaminophen,oval-shaped, white tablets bisected on one sideand debossed with WATSON 517 on the other side,supplied in bottles of 100 and 500.

10 mg/750 mg       10 mg hydrocodone bitartrate and 750 mg acetaminophen, capsule-shaped, yellow tablets bisected on one side and debossed with WATSON 3228 on the other side, supplied in bottles of 100.

Store at 20 degrees - 25 degrees C (68 degrees - 77 degrees F). [See USP controlled room temperature.]

Dispense in a tight, light-resistant container with a child-resistant closure.

Watson Laboratories, Inc.                                    Revised: March 2007
Corona, CA 92880 USA                                                            0907B
                                                                                              14715




Theramine™ PRODUCT INFORMATION

Theramine (U.S. patent pending) capsules by oral administration. A specially formulated Medical Food product, consisting of a proprietary blend of amino acids and polyphenol ingredients in specific proportions, for the dietary management of the metabolic processes associated with pain disorders and inflammatory conditions. (PD) (IC).
Must be administered under physician supervision.

Medical Foods
Medical Food products are often used in hospitals (e.g., for burn victims or kidney dialysis patients) and outside of a hospital setting under a physician’s care for the dietary management of diseases in patients with particular medical or metabolic needs due to their disease or condition. Congress defined "Medical Food" in the Orphan Drug Act and Amendments of 1988 as "a food which is formulated to be consumed or administered enterally [or orally] under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation." Medical Foods are complex formulated products, requiring sophisticated and exacting technology. Theramine has been developed, manufactured, and labeled in accordance with both the statutory and the FDA regulatory definition of a Medical Food. Theramine must be used while the patient is under the ongoing care of a physician.

PAIN DISORDERS (PD) INFLAMMATORY CONDITIONS (IC)
PD and IC as a Metabolic Deficiency Disease
A critical component of the definition of a Medical Food is the requirement for a distinctive nutritional deficiency. FDA scientists have proposed a physiologic definition of a distinctive nutritional deficiency as follows: “the dietary management of patients with specific diseases requires, in some instances, the ability to meet nutritional requirements that differ substantially from the needs of healthy persons. For example, in establishing the recommended dietary allowances for general, healthy population, the Food and Nutrition Board of the Institute of Medicine National Academy of Sciences, recognized that different or distinctive physiologic requirements may exist for certain persons with "special nutritional needs arising from metabolic disorders, chronic diseases, injuries, premature birth, other medical conditions and drug therapies. Thus, the distinctive nutritional needs associated with a disease reflects the total amount needed by a healthy person to support life or maintain homeostasis, adjusted for the distinctive changes in the nutritional needs of the patient as a result of the effects of the disease process on absorption, metabolism and excretion.” It was also proposed that in patients with certain disease states who respond to nutritional therapies, a physiologic deficiency of the nutrient is assumed to exist. For example, if a patient with pain disorders responds to a tryptophan formulation by decreasing perceived pain, a deficiency of tryptophan is assumed to exist.

Patients with pain disorders and inflammatory conditions are known to have nutritional deficiencies of tryptophan, choline, arginine, GABA, flavonoids, and certain antioxidants. Patients with pain disorders and inflammatory conditions frequently exhibit reduced plasma levels of tryptophan and GABA and have been shown to respond to oral administration of GABA, arginine, tryptophan, or a 5-hydoxytryptophan formulation. Research has shown that tryptophan, arginine or GABA reduced diets result in a fall of circulating tryptophan, arginine, and/or GABA. Patients with pain disorders frequently exhibit activation of the degradation pathways that increases the turnover of GABA, arginine and/or tryptophan leading to a reduced level of production of serotonin, GABA or nitric oxide for a given precursor blood level. Research has also shown that a genetic predisposition to accelerated degradation can lead to increased precursor requirements in certain patients with pain disorders and inflammatory conditions.

Choline is required to fully potentiate acetylcholine synthesis by brain neurons. A deficiency of choline leads to reduced acetylcholine production by the neurons. Flavonoids potentiate the production of acetylcholine by the neurons thereby reducing delta pain. Diets deficient in flavonoid rich foods and choline result in inadequate flavonoid concentrations, impeding acetylcholine production in certain patients with pain disorders and/or inflammatory conditions. Acetylcholine in pre-synaptic ganglia is necessary for the production of serotonin and nitric oxide in post-synaptic ganglia. Provision of tryptophan, arginine, GABA, choline and flavonoids with antioxidants, in specific proportions can restore the production of beneficial serotonin, nitric oxide, and acetylcholine, thereby reducing the perception of pain and reducing inflammation. L-Histidine is known to produce brain histamine that stimulates production of ACTH.

PRODUCT DESCRIPTION
Primary Ingredients
Theramine consists of a proprietary blend of amino acids, cocoa, caffeine, cinnamon, and flavonoids in specific proportions. These ingredients fall into the category of Generally Regarded as Safe” (GRAS) as defined by the Food and Drug Administration (FDA) (Sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act). A GRAS substance is distinguished from a food additive on the basis of the common knowledge about the safety of the substance for its intended use. The standard for an ingredient to achieve GRAS status requires not only technical demonstration of non-toxicity and safety, but also general recognition of safety through widespread usage and agreement of that safety by experts in the field. Many ingredients have been determined by the U.S. Food and Drug Administration (FDA) to be GRAS, and are listed as such by regulation, in Volume 21 Code of Federal Regulations (CFR) Sections 182, 184, and 186.

Amino Acids
Amino Acids are the building blocks of protein. All amino acids are GRAS listed as they have been ingested by humans for thousands of years. The doses of the amino acids in Theramine are equivalent to those found in the usual human diet. Patients with pain disorders may require an increased amount of certain amino acids that cannot be obtained from normal diet alone. Tryptophan, for example, is an obligatory amino acid. The body cannot make tryptophan and must obtain tryptophan from the diet. Tryptophan is needed to produce serotonin. Serotonin is required to reduce pain. Patients with pain disorders and inflammatory conditions have altered serotonin metabolism. Some patients with pain disorders and inflammatory conditions have a resistance to the use of tryptophan that is similar to the mechanism found in insulin resistance. Patients with pain disorders and inflammatory conditions cannot acquire sufficient tryptophan from the diet to alter the perception of pain and the inflammatory process without ingesting a prohibitively large amount of calories, particularly calories from protein.

Flavonoids
Flavonoids are a group of phytochemical compounds found in all vascular plants including fruits and vegetables. They are a part of a larger class of compounds known as polyphenols. Many of the therapeutic or health benefits of colored fruits and vegetables, cocoa, red wine, and green tea are directly related to their flavonoid content. The specially formulated flavonoids found in Theramine cannot be obtained from conventional foods in the necessary proportions to elicit a therapeutic response.

Other Ingredients
Theramine contains the following inactive or other ingredients, as fillers, excipients, and colorings: magnesium stearate, microcrystalline cellulose, Maltodextrin NF, gelatin (as the capsule material).
Physical Description
Theramine is a yellow to light brown powder. Theramine contains L-Glutamine, L-Arginine, L-Histidine, and L-Serine, 5-Hydroxytryptophan as Griffonia Seed Extract, GABA, Choline Bitartrate, Cinnamon, Cocoa, Hydrolyzed Whey Protein, and Grape Seed Extract.

CLINICAL PHARMACOLOGY


Mechanism of Action
Theramine acts by restoring and maintaining the balance of the neurotransmitters; GABA, nitric oxide, serotonin, and acetylcholine that are associated with pain disorders and inflammatory conditions. Theramine stimulates the production ACTH to reduce inflammation.

Metabolism
The amino acids in Theramine are primarily absorbed by the stomach and small intestines. All cells metabolize the amino acids in Theramine. Circulating tryptophan, arginine and choline blood levels determine the production of serotonin, nitric oxide, and acetylcholine.

Excretion
Theramine is not an inhibitor of cytochrome P450 1A2, 2C9, 2C19, 2D6, or 3A4. These isoenzymes are principally responsible for 95% of all detoxification of drugs, with CYP3A4 being responsible for detoxification of roughly 50% of drugs. Amino acids do not appear to have an effect on drug metabolizing enzymes.

Uses

INDICATIONS FOR USE
Theramine is intended for the clinical dietary management of the metabolic processes of pain disorders and inflammatory conditions.

CLINICAL EXPERIENCE
Administration of Theramine has demonstrated significant reduction in symptoms of pain and inflammation in patients with acute and chronic pain when used for the dietary management of the metabolic processes associated with pain disorders and inflammatory conditions. Administration of Theramine results in the induction and maintenance of pain relief in patients with pain disorders and inflammatory conditions.

PRECAUTIONS AND CONTRAINDICATIONS
Theramine is contraindicated in an extremely small number of patients with hypersensitivity to any of the nutritional components of Theramine.

ADVERSE REACTIONS
Oral supplementation with L-tryptophan, L-arginine or choline at high doses up to 15 grams daily is generally well tolerated. The most common adverse reactions of higher doses — from 15 to 30 grams daily — are nausea, abdominal cramps, and diarrhea. Some patients may experience these symptoms at lower doses. The total combined amount of amino acids in each Theramine capsule does not exceed 400 mg.

DRUG INTERACTIONS
Theramine does not directly influence the pharmacokinetics of prescription drugs. Clinical experience has shown that administration of Theramine may allow for lowering the dose of co-administered drugs under physician supervision.

OVERDOSE
There is a negligible risk of overdose with Theramine as the total dosage of amino acids in a one month supply (90 capsules) is less than 36 grams. Overdose symptoms may include diarrhea, weakness, and nausea.

POST-MARKETING SURVEILLANCE
Post-marketing surveillance has shown no serious adverse reactions. Reported cases of mild rash and itching may have been associated with allergies to Theramine flavonoid ingredients, including cinnamon, cocoa, and chocolate. These reactions were transient in nature and subsided within 24 hours.

DOSAGE AND ADMINISTRATION
Recommended Administration
For the dietary management of the metabolic processes associated with pain disorders and inflammatory conditions. Take (2) capsules one to three times daily or as directed by physician. As with most amino acid formulations Theramine should be taken without food to increase the absorption of key ingredients.

How Supplied
Theramine is supplied in purple and white, size 0 capsules in bottles of 60 or 90 capsules.

Physician Supervision
Theramine is a Medical Food product available by prescription only and must be used while the patient is under ongoing physician supervision.

Storage
Store at room temperature, 59-86OF (15-30OC) Protect from light and moisture. Theramine is supplied to physicians in a recyclable plastic bottle with a child-resistant cap.

U.S. patent pending.
Manufactured by Arizona Nutritional Supplements, Inc. Chandler AZ 85225
Distributed by Physician Therapeutics LLC, Los Angeles, CA 90077. www.ptlcentral.com
© Copyright 2003-2006, Physician Therapeutics LLC, all rights reserved

Ingredients:
Each serving (per 2 capsules) contains:
Proprietary Amino Acid Blend Griffonia Seed Extract (5-HTP), Whey Protein Hydrolysate, L-Arginine, L-Histidine (as L-Histidine HCI), L-Glutamine, L-Serine, Gamma Amino Butyric Acid, Choline Bitartrate, Cocoa (6% Theobromine) (fruit), Grape Extract (95% Polyphenols) (seed), Cinnamon (bark)

Other Ingredients: Gelatin, Silicon Dioxide, Tricalcium phosphate, Vegetable Megnesium Stearate, Cellulose, FD C Blue 1, FD C red 3, titanium dioxide.

Directions for use:

Must be administered under medical supervision.

For adults only. As a Medical Food, take one (1) or two (2) capsules every four hours or as directed by your medical practicioner.

For the dietary management of Myalgia.

Contains no added sugar, starch , wheat, yeast, preservatives, artificial flavor.

Storage:

Keep tightly closed in a cool dry place 8-38 degrees C (45-90 degrees F), relative humidity, below 50 percent.

Warning: Keep this product out of the reach of children.


Theracodophen-Low-90

Theracodophen-Low-90

Theracodophen-Low-90

Theracodophen-Low-90

HYDROCODONE BITARTRATE, ACETAMINOPHEN, .GAMMA.-AMINOBUTYRIC ACID KIT

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:68405-298
Route of Administration DEA Schedule

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:68405-298-36 1 in 1 KIT

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
2011-02-02


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.